{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m nalidixic acid
to a specific field?
Status:
Investigational
Source:
NCT00004154: Phase 3 Interventional Completed Bladder Cancer
(1998)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Fenretinide (4-HPR) is an orally-active synthetic phenylretinamide analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities. Fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in some tumor cell types. This agent also inhibits tumor growth by modulating angiogenesis-associated growth factors and their receptors and exhibits retinoid receptor-independent apoptotic properties. Phase III clinical trial data has suggested that fenretinide reduces breast cancer relapse in pre-menopausal women. Fenretinide is the most studied retinoid in breast cancer chemoprevention clinical trials due to its selective accumulation in breast tissue and its favorable toxicological profile. This agent showed a significative reduction of the incidence of second breast tumors in premenopausal women confirmed after 15-year followups. Fenretinide, a drug being developed by Sirion Therapeutics, slowed the progression of advanced dry age-related macular degeneration (AMD) by 45 percent for people receiving a higher dose of the treatment in a Phase II clinical trial. Sirion has been granted a Fast Track designation for the treatment by the FDA. Fenretinide is in phase II clinical trials for the treatment of B-cell lymphoma, chronic lymphocytic leukemia. It is also in phase I clinical trials for the treatment of cystic fibrosis.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Bucrylate (isobutyl cyanoacrylate) is a liquid tissue adhesive for transcatheter embolization. It is used in radiological and endoscopic interventions to occlude vessels and to stop bleedings. In comparison with sponges, coils and plugs, bucrylate is inexpensive and achieves immediate, irreversible and complete occlusion of the vessel irrespective of coagulation deficiencies.
Class (Stereo):
CHEMICAL (RACEMIC)
Tixanox is an antiallergic drug. It blocks histamine release from human lung induced by anti-IgE. Tixanox has been shown to be orally active against exercise-induced asthma in man.
Class (Stereo):
CHEMICAL (ACHIRAL)
FLUFENISAL is a compound related to aspirin structurally, chemically, and pharmacologically. It was in clinical development as an analgesic and anti-inflammatory agent. However, its development was discontinued due to lack of sufficient superiority over aspirin.
Status:
Investigational
Source:
NCT03440632: Not Applicable Interventional Completed Cerebral Palsy
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Zearalenone (ZEN) is a toxic non-steroidal mycoestrogen produced by fungi that widely contaminate agricultural products, eliciting estrogenic responses by mimicking sex steroid hormones. Zearalenone is biosynthesised through a polyketide pathway by a variety of Fusarium fungi including Fusarium graminearum (Gibberella zeae), Fusarium culmorum, Fusarium equiseti, Fusarium crookwellense, Fusarium cerealis and Fusarium semitectum. Zearalenone and its derivatives share similar molecular mechanisms and activity with estrogens. They interact with the estrogen receptors (ERa and ERb) leading to functional and morphological changes in the reproductive system in both animals and humans. Zearalenone exposure is associated with the estrogenic syndrome and infertility in animals and premature thelarche and precocious puberty in girls. In animal models, it was found that prepubertal exposure to a low dose of Zearalenone, decreased breast cancer risk. When prepubertal rats were treated with 20 lg (1 mg ⁄ kg body weight) of Zearalenone, a significant reduction of both the incidence and multiplicity of DMBA-induced mammary tumours was noted. Zearalenone has been used to treat postmenopausal symptoms in women.
Status:
Investigational
Source:
NCT04464070: Early Phase 1 Interventional Enrolling by invitation Metabolism of Prostaglandin D2
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
PGD2 (Prostaglandin D2) is a major cellular regulator, has been shown to bind different receptors: D prostanoid receptor (DP) and chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). PGD2 reportedly inhibits platelet aggregation, the proliferation of cells, and activation of neutrophils. This compound is also a potent vasodilator that also relaxes smooth muscle but causes contraction of the bronchial airways. PGD2 promotes T cell migration via CRTH2 and aggravates asthma. In contrast, there have been some studies suggesting that PGD2 exerts anti-inflammatory effects via DP, such as inhibiting the migration and activation of neutrophils, basophils, dendritic cells and T cells. Elevated levels of prostaglandin D2 (PGD2) have been shown to be present in the bald scalp of androgenic alopecia (AGA) patients and was suggested the PGD(2)-GPR44 pathway as a potential target for treatment. Also was revealed, that PGD2 might be a new target for asthma therapy, PGD2 in serum and BALF were lower in the treated group than in the untreated group.
Class (Stereo):
CHEMICAL (ACHIRAL)
Lifibrate is the antihyperlipidemic agent. It is a potent hepatic peroxisome proliferator. Administration of lifibrate at a dietary concentration of 0.15% for 3 weeks, increased the activity of catalase in both liver and kidney of male wild type (Cs-a strain) mice. The hypolipidemic activity of lifibrate is eight to nine times greater than that of chlorphenoxy isobutyric acid ethyl ester in the male Wistar rat.
Status:
Investigational
Source:
NCT01012947: Phase 1 Interventional Completed Alteration of Cognitive Function
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (MIXED)
Nisobamate is a tranquilizer, sedative and hypnotic.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Gloximonam (SQ-82531) is a beta-lactam antibiotic. This is a class of antibiotics that contains a beta-lactam ring in their molecular structure, such as penicillin derivatives. Gloximonam is orally absorbed and has shown anti-bacterial activity against different bacteria of the Enterobacteriaceae and Haemophilus influenzae families. Gloximonam is not effective against staphylococci and strict anaerobes (like aztreonam) and (unlike aztreonam) against Pseudomonas aeruginosa.
